Multi‐institutional, prospective, randomized, double‐blind, placebo‐controlled phase IIb trial of the tumor lysate, particle‐loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high‐risk melanoma patients: A subgroup analysis

BACKGROUND: Checkpoint inhibitors (CPI) in combination with cell‐based vaccines may produce synergistic antitumor immunity. The primary analysis of the randomized and blinded phase IIb trial in resected stage III/IV melanoma demonstrated TLPLDC is safe and improved 24‐month disease‐free survival (DF...

Descripción completa

Detalles Bibliográficos
Autores principales: Chick, Robert C., Faries, Mark B., Hale, Diane F., Kemp Bohan, Phillip M, Hickerson, Annelies T., Vreeland, Timothy J., Myers, John W., Cindass, Jessica L., Brown, Tommy A., Hyngstrom, John, Berger, Adam C., Jakub, James W., Sussman, Jeffrey J., Shaheen, Montaser, Clifton, Guy T., Park, Hyohyun, Sloan, Amanda J., Wagner, Thomas, Peoples, George E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267143/
https://www.ncbi.nlm.nih.gov/pubmed/33982452
http://dx.doi.org/10.1002/cam4.3969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267143/
https://www.ncbi.nlm.nih.gov/pubmed/33982452
http://dx.doi.org/10.1002/cam4.3969

Ejemplares similares